Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for ...

SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a ...

Treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and renal disease with the oral C5a receptor inhibitor avacopan (Tavneos, ChemoCentryx) provides significant recovery ...

ChemoCentryx CCXI announced that the FDA has approved its lead candidate, avacopan, for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis ...

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...

Patients who received plasmapheresis for ANCA-associated vasculitis vs those who did not were more likely to have had AKI, AKI requiring dialysis, hypoxia, and respiratory failure requiring mechanical ...

Intravenous drip Use of the drug resulted in remission of severe pulmonary and cutaneous ANCA-associated vasculitis that resisted intensive conventional treatment. Daratumumab, a monoclonal antibody, ...

The FDA approved the oral complement 5a receptor inhibitor avacopan (Tavneos) for the treatment of severe, active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, drugmaker ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, ANCA Vasculitis pipeline constitutes 12+ key companies continuously working towards developing 12+ ANCA ...

Objective The aim of this study was to investigate the relationship between antineutrophil cytoplasmic antibodies (ANCA) ...

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces that it will begin dispensing TAVNEOS™ (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, ...